Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

被引：4
|
作者：
Matsumoto, Yoshiya [1 ,2 ]
Koh, Yasuhiro [2 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 07期
关键词：
epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden; PD-L1; EXPRESSION; MUTATION INCIDENCE; OPEN-LABEL; PHASE IB; DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB; BLOCKADE; INFILTRATION; CHEMOTHERAPY;
D O I：
10.2217/imt-2019-0213
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：431 / 438
页数：8
相关论文
共 50 条
  • [31] Prognostic value of tumor microenvironment (TME) features in advanced, EGFR-mutant non-small cell lung cancer (NSCLC)
    Zullo, Lodovica
    Ghigna, Maria Rosa
    Zrafi, Wael Salem
    Marinello, Arianna
    Vasseur, Damien
    Frelaut, Maxime
    Abdayem, Pamela
    Tagliamento, Marco
    Lavaud, Pernelle
    Gazzah, Anas
    Scoazec, Jean-Yves
    Remon, Jordi
    Barlesi, Fabrice
    Besse, Benjamin
    Planchard, David
    Aldea, Mihaela
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [32] YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
    Li, Ling-Chen
    Chen, Xie-Wan
    Fang, Ling
    Jian, Chun-Li
    Yu, Yong-Xin
    Liao, Xing-Yun
    Sun, Jian-Guo
    CANADIAN RESPIRATORY JOURNAL, 2023, 2023
  • [33] FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer
    Gold, Kathryn A.
    Erasmus, Jeremy J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1131 - 1132
  • [34] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
    Zhang, Hongye
    Wang, Ruiyu
    Wang, Mingxia
    Luo, Judong
    Liu, Changmin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
  • [35] Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
    Wang, Haiyang
    Yu, Xiaoqing
    Fan, Yun
    Jiang, Youhua
    ONCOTARGETS AND THERAPY, 2018, 11 : 2149 - 2155
  • [36] Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
    Lim, Jeong Uk
    Jung, Junyang
    Kim, Yeon Wook
    Kim, Chi Young
    Lee, Sang Hoon
    Park, Dong Won
    Choi, Sue In
    Ji, Wonjun
    Yeo, Chang Dong
    Lee, Seung Hyeun
    BIOMEDICINES, 2025, 13 (02)
  • [37] Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
    Kim, C.
    Xi, L.
    Cultraro, C.
    Pham, T.
    Roper, N.
    Bagheri, M.
    Rajan, A.
    Beeler, J.
    Jones, G.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S478 - S478
  • [38] EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
    Shiiya, Akihiko
    Noguchi, Takuro
    Tomaru, Utano
    Ariga, Shin
    Takashima, Yuta
    Ohhara, Yoshihito
    Taguchi, Jun
    Takeuchi, Satoshi
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Koizumi, Tomonobu
    Matsuno, Yoshihiro
    Shinagawa, Naofumi
    Sakakibara-Konishi, Jun
    Dosaka-Akita, Hirotoshi
    CANCER SCIENCE, 2023, 114 (04) : 1270 - 1283
  • [39] EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Ke, E-E
    Wu, Yi-Long
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (11) : 887 - 903
  • [40] Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
    Lamberti, Giuseppe
    Andrini, Elisa
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1831 - S1834
12345